KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Other financing activities: 2012-2016

Historic Other financing activities for Jazz Pharmaceuticals (JAZZ) over the last 4 years, with Sep 2016 value amounting to -$3.5 million.

  • Jazz Pharmaceuticals' Other financing activities fell 994.69% to -$3.5 million in Q3 2016 from the same period last year, while for Sep 2016 it was $320,000, marking a year-over-year increase of 112.53%. This contributed to the annual value of $1.8 million for FY2014, which is N/A change from last year.
  • As of Q3 2016, Jazz Pharmaceuticals' Other financing activities stood at -$3.5 million, which was up 21.01% from -$4.4 million recorded in Q2 2016.
  • Jazz Pharmaceuticals' 5-year Other financing activities high stood at $10.6 million for Q1 2015, and its period low was -$10.6 million during Q2 2015.
  • For the 3-year period, Jazz Pharmaceuticals' Other financing activities averaged around $167,364, with its median value being -$320,000 (2015).
  • As far as peak fluctuations go, Jazz Pharmaceuticals' Other financing activities surged by 3,903.66% in 2014, and later crashed by 994.69% in 2016.
  • Jazz Pharmaceuticals' Other financing activities (Quarterly) stood at $5.5 million in 2012, then soared by 104.16% to $82,000 in 2013, then spiked by 3,903.66% to -$2.2 million in 2014, then skyrocketed by 114.32% to $320,000 in 2015, then plummeted by 994.69% to -$3.5 million in 2016.
  • Its Other financing activities was -$3.5 million in Q3 2016, compared to -$4.4 million in Q2 2016 and $7.9 million in Q1 2016.